Stanford University. Millegen Biotech and University of Copenhagen has collaborated supported by Juvenile Diabetes Research Foundation in the development of a new recombinant bioluminescent fusion protein scFv-Gluc, with the aim of testing the new format for in vivo noninvasive biolumeniscent imaging (BLI) of beta-cells in whole animals and pancreas tissue. The first fusion protein is currently under in vitro testing.
News
Bioluminescent recombinant IC2 developed in collaboration with Stanford University
Welcome to ImmunoSigns
ImmunoSigns is a Biotech company founded in 1996. We offer you help in project management and R&D activities within biotechnology and immunodetection.
The core competance of ImmunoSigns is development and production of polyclonal and monoclonal antibodies and design and production of novel immunoassays and diagnostic kits, especially within the clinical area of diabetes and obesity.
© 2020 ImmunoSigns. All Rights Reserved.
Powered by WordPress. Designed by 